Introduction
Neutrophils are the most abundant leukocytes in mammals and, as a first line of defense against microbes, they play crucial roles in innate immune responses. The homeostasis of neutrophils is maintained by balancing their short lifespan in the circulation with their regulated release from the bone marrow. Neutrophils have various types of granules, containing hundreds of proteins. These include bactericidal proteins, some of them with important effects on innate and adaptive immune responses, such as a-defensins, the cathelicidin human cationic antimicrobial protein of 18 kDa, and lactoferrin, among others. LL-37, a proteolytic product of human cationic antimicrobial protein of 18 kDa, has important chemotactic and immunostimulatory effects, as discussed below (1).
The mechanisms used by neutrophils to eliminate microbes include phagocytosis, generation of reactive oxygen species (ROS), and the release of microbicidal molecules from granules (degranulation). In 2004, another distinct antimicrobial activity was described: neutrophils extrude a meshwork of chromatin fibers that are decorated with granule-derived antimicrobial peptides and enzymes such as neutrophil elastase (Fig. 1), cathepsin G, and myeloperoxidase (MPO) (2). These structures, called neutrophil extracellular traps (NETs), represent an important strategy to immobilize and kill invading microorganisms. The NET scaffold consists of chromatin fibers with a diameter of 15–17 nm; DNA and histones represent the major NET constituents (2). Mass spectrometry has identified various additional proteins associated with NETs, including components from various types of granules. Although conserved proteins are found in extracellular trap fractions, it is still unclear whether the peptide composition of these structures may vary depending on the specific stimulus that promotes NET formation (3, 4).
Cont..
https://www.jimmunol.org/content/189/6/2689.long
Recent VNRX News
- Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems • PR Newswire (US) • 03/06/2026 01:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:32:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:32:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:32:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:31:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:31:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:30:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:30:29 PM
- VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution • PR Newswire (US) • 02/25/2026 01:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 10:15:32 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/20/2026 05:15:15 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/11/2026 10:05:44 PM
- Volition Announces the Appointment of New Distributor for Nu.Q® Discover • PR Newswire (US) • 02/10/2026 01:07:00 PM
- VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards • PR Newswire (US) • 02/09/2026 10:20:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/09/2026 10:16:09 PM
- Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation • PR Newswire (US) • 02/04/2026 01:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 09:05:05 PM
- VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays • PR Newswire (US) • 01/30/2026 01:50:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
